Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with European Union patent no EP 3 134 426 B1.
Patent EP 3 134 426 B1
.pdf
Download PDF • 1.91MB